Dr. David E. Gilham, Ph.D.

Scientific Advisory Board Member

Dr. David Gilham is a globally recognised expert in engineered T‑cell immunotherapies with over two decades of leadership in CAR‑T and adoptive cell therapy research and translation. He brings deep scientific expertise and strategic insight into the design, preclinical development, and clinical translation of next‑generation cellular immunotherapies.

Dr Gilham is the former Vice President of Research & Development and Chief Scientific Officer of Celyad Oncology, where he was instrumental in developing CAR‑T and allogeneic cellular therapies. He also led the University of Manchester Clinical and Experimental Immunotherapy Group, has authored over 75 peer‑reviewed scientific publications, and driven preclinical programmes that supported Phase I/II clinical investigation of gene‑modified T cells.

Dr. Gilham has deep mechanistic understanding of T‑cell engineering and a strong track record in translating complex immunotherapies into clinical settings.